Research map: Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer

Back to the article

Papers in this map

  1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis · Patricia Cortazar · 2014 · 4867 citations · Cited by this paper
  2. Ketamine versus Magnesium Sulphate as Adjuvants to Bupivacaine in Pectoral Nerve Blocks for Mastectomy: A Randomized, Double-Blind Trial · Doaa Moaz Sayem · 2026 · Cites this paper
  3. Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females · 2026 · Related
  4. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update · Antonio C. Wolff · 2018 · 2542 citations · Cited by this paper
  5. Effect of Treatment Sequencing in Older Adults With Early Breast Cancer. Insights From a Retrospective Single-Institution Cohort · 2026 · Related
  6. Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial · Ian E. Smith · 2005 · 780 citations · Cited by this paper
  7. Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping · 2026 · Related
  8. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study · Wolfgang EIERMANN · 2001 · 719 citations · Cited by this paper
  9. Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care · 2026 · Related
  10. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer · Aditya Bardia · 2024 · 465 citations · Cited by this paper
  11. Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer · 2026 · Related
  12. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors · Leah Natasha Klapper · 1999 · 451 citations · Cited by this paper
  13. Association of Regional Anesthesia With Reduced Post-discharge Opioid Prescriptions Following Immediate Autologous Breast Reconstruction: An ACS-NSQIP Analysis · 2026 · Related
  14. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer · Владимир Федорович Семиглазов · 2007 · 334 citations · Cited by this paper
  15. Evaluation of Absorbable Hemostatic Powder on Post-operative Outcomes in Patients Undergoing Mastectomy · 2026 · Related
  16. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial · Ian Smith · 2020 · 330 citations · Cited by this paper
  17. Feasibility of Same Day Mastectomy Discharge in a Safety Net Hospital in Memphis, TN · 2026 · Related
  18. The HER2-low revolution in breast oncology: steps forward and emerging challenges · Eleonora Nicolò · 2023 · 73 citations · Cited by this paper
  19. CTSG suppresses breast cancer progression by inhibiting the EGFR/ERK signaling pathway and enhancing CD8⁺ T cell activation · 2026 · Related
  20. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer · Isabel Pinhel · 2012 · 66 citations · Cited by this paper
  21. The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer · 2026 · Related
  22. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer · Hee Jeong Kim · 2020 · 65 citations · Cited by this paper
  23. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France · Ombline de Calbiac · 2022 · 38 citations · Cited by this paper
  24. Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases · Siji Zhu · 2023 · 33 citations · Cited by this paper
  25. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) · Liang Xu · 2018 · 31 citations · Cited by this paper
  26. Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016) · Macy M. Goldbach · 2021 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)